Profile data is unavailable for this security.
About the company
Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The Company is commercializing sugarBEAT and proBEAT. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and also be used to screen pre-diabetic patients. The sugarBEAT device extracts from analytes, such as glucose, from the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service.
- Revenue in USD (TTM)0.00
- Net income in USD-10.65m
- Incorporated2013
- Employees36.00
- LocationNemaura Medical Inc57 W 57th StNEW YORK 10019-2802United StatesUSA
- Phone+44 (150) 922-2912
- Websitehttps://nemauramedical.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SETO Holdings Inc | 4.96m | -652.00k | 1.02m | 18.00 | -- | 0.0926 | -- | 0.2057 | -0.056 | -0.056 | 0.3994 | 0.134 | 1.57 | 2.65 | 8.51 | -- | -20.70 | 3.84 | -29.07 | 5.95 | 52.83 | 52.44 | -13.15 | 3.92 | 0.9921 | 1.24 | 0.304 | 0.00 | 19.01 | 5.44 | -61.23 | -- | -- | -- |
SPO Global Inc | 838.00k | -540.00k | 1.03m | 2.00 | -- | -- | -- | 1.23 | -85.99 | -85.99 | 131.76 | -476.56 | 1.76 | -- | -- | -- | -113.56 | -305.39 | -- | -- | 31.15 | 27.31 | -64.44 | -384.85 | -- | -1.45 | -- | -- | -17.09 | -15.13 | 13.03 | -- | -- | -- |
Remedent Inc | 1.13m | -259.38k | 1.10m | 16.00 | -- | 0.2324 | -- | 0.9743 | -0.013 | -0.013 | 0.0565 | 0.2367 | 0.1474 | 3.45 | 2.69 | -- | -3.24 | 7.35 | -5.20 | 12.93 | 65.38 | 64.60 | -21.97 | 21.20 | 0.2033 | -0.772 | 0.00 | -- | -33.63 | -21.70 | -140.31 | -- | -- | -- |
Invivo Therapeutics Holdings Corp | 0.00 | -9.33m | 1.21m | 6.00 | -- | 0.1358 | -- | -- | -3.53 | -3.53 | 0.00 | 2.87 | 0.00 | -- | -- | 0.00 | -81.32 | -73.69 | -94.35 | -85.63 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -6.01 | -- | 19.74 | -- |
Escalon Medical Corp | 11.65m | -296.71k | 1.26m | 38.00 | -- | 1.22 | -- | 0.1083 | -0.0401 | -0.0401 | 1.29 | 0.2259 | 2.40 | 3.75 | 7.51 | 306,456.30 | -1.26 | -1.76 | -2.84 | -3.67 | 44.07 | 44.57 | -0.5265 | -0.9114 | 0.8927 | -1.62 | 0.1584 | -- | 13.80 | 1.33 | 760.89 | -17.06 | -19.85 | -- |
Acutus Medical Inc | 9.55m | -9.70m | 1.26m | 233.00 | -- | -- | -- | 0.1323 | -0.3301 | 0.0956 | 0.3261 | -0.1353 | 0.1211 | 1.14 | 1.46 | 40,974.25 | -12.30 | -46.76 | -14.84 | -56.88 | -24.07 | -89.12 | -101.56 | -773.49 | 2.89 | -4.64 | 1.13 | -- | 136.36 | 27.03 | -141.35 | -- | -35.99 | -- |
Grapefruit USA Inc | 34.85k | -4.37m | 1.27m | 9.00 | -- | -- | -- | 36.52 | -0.008 | -0.008 | 0.00006 | -0.0101 | 0.0121 | 1.31 | 0.2259 | 3,872.22 | -151.85 | -268.93 | -- | -- | -1,304.65 | -10.09 | -12,531.68 | -408.87 | 0.0388 | -1.50 | -- | -- | -83.96 | 77.87 | -35.68 | -- | -- | -- |
Nemaura Medical Inc | 0.00 | -10.65m | 1.30m | 36.00 | -- | -- | -- | -- | -0.3787 | -0.3787 | 0.00 | -0.6169 | 0.00 | 0.00 | -- | 0.00 | -117.49 | -58.18 | -- | -131.96 | -- | -- | -- | -7,384.83 | 0.0305 | -1.47 | 10.81 | -- | -84.71 | -- | -1.85 | -- | 64.14 | -- |
Bone Biologics Corp | 0.00 | -6.10m | 1.72m | 2.00 | -- | 0.4315 | -- | -- | -23.10 | -23.10 | 0.00 | 3.62 | 0.00 | -- | -- | 0.00 | -114.93 | -98.31 | -189.37 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -502.76 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
XTX Markets LLCas of 31 Mar 2024 | 18.87k | 0.07% |
BlackRock Advisors LLCas of 26 Feb 2021 | 5.60k | 0.02% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 2.01k | 0.01% |
Desjardins Securities, Inc.as of 31 Mar 2024 | 1.95k | 0.01% |
Alyeska Investment Group LPas of 31 Mar 2024 | 0.00 | 0.00% |
Tower Research Capital LLCas of 31 Mar 2024 | 0.00 | 0.00% |
UBS Securities LLCas of 31 Mar 2024 | 0.00 | 0.00% |
Citadel Securities LLCas of 31 Mar 2024 | 0.00 | 0.00% |
Salomon & Ludwin LLCas of 31 Mar 2024 | 0.00 | 0.00% |
Wells Fargo Advisors Financial Network LLCas of 31 Mar 2024 | 0.00 | 0.00% |